40% of ischemic strokes never have cause determined. Knowing cause of stroke is critical to patient outcomes and reducing costs.
Ischemia Care's pipeline is based upon over 15 years of publications in major peer reviewed journals with sensitivity and specificty > 95%.
BASE (NCT02014896) is a prospective trial designed to validate over 15 years of peer reviewed clinical findings leading to commercilization of a platform of diagnostic testing, including point of care.Read more
Proven management team and advisors (2 IPOs, multiple exits, former Chief of Cardiology at Stanford), KOLs in the field of stroke (author of Stroke Guidelines), strategic support (Affymetrix, Medtronics), and leading stroke centers.Read more
Recent News and Notes
Using RNA expression from whole blood, ISC has developed a gene based classifier (or signature) to differentaite cardioembolic from atheroembolic (large vessel) ischemic stroke.
Over 900 subjects enrolled and over 3,500 samples collected in BASE since December 2013, making BASE one of the most successful biomarker or stroke clinical trials.
Company closes on a $1.7M round to support commercilization.